Gånheim A, Gånheim A, Jöchle W
Swedish National Stud, Veterinary Services, Flyinge, Sweden.
Acta Vet Scand. 1995;36(4):393-400. doi: 10.1186/BF03547654.
In a blinded trial, the effectiveness and safety of 2.2 mg of the GnRH analog deslorelin acetate, administered in a short-term implant (STI) to normally cycling mares in estrus with a dominant ovarian follicle of 30 mm in diameter or larger, were evaluated, using a placebo implant as a negative control. A total of 39 mares received treatments at admittance with pre-randomized implants containing either 2.2 mg or 0 mg deslorelin. Mares were teased daily and examined rectally with ultrasound at 24 h intervals to determine time to ovulation and duration of estrus. The number of breedings and the pregnancy rate at 18 (+/- 3) and 38 (+/- 3) days were recorded, as were systemic side effects and local reactions at the implantation sites. Pregnancies resulting from breedings during the treatment estrus and/or from breedings during the next estrus were followed and the early and late pregnancy loss rate, the number of pregnancies going to term and of live-born foals was recorded. Mean follicle diameter at treatment was not significantly different between the deslorelin and placebo treatment group with 41.6 mm and 40.8 mm, respectively. Treatment with deslorelin STI reduced the time interval to ovulation significantly from 69.5 +/- 25.48 h to 42.7 +/- 12.35 h (p < 0.001). The percentage of mares having ovulated within 48 h rose from 26.3% to 95.0%, respectively, for placebo and deslorelin STI (p < 0.001). As a consequence, the duration of estrus in days and the percent of animals requiring more than 1 breeding were significantly reduced in deslorelin treated animals from 5.4 days to 4.6 days, and from 55.6% to 5.0%, respectively (p = 0.009 and = 0.001). The percent of mares pregnant from breedings at the treatment estrus (65.0% versus 44.4%) or the next estrus (83.3% versus 92.3%) was satisfactory and similar for deslorelin and placebo treated mares (p > 0.005), and in 70.0% and 66.7% of these once or twice bred mares did pregnancies go to term and live foals were born.
在一项双盲试验中,评估了将2.2毫克促性腺激素释放激素类似物醋酸地洛瑞林以短期植入物(STI)的形式给予处于发情期、具有直径30毫米或更大优势卵泡的正常发情母马的有效性和安全性,使用安慰剂植入物作为阴性对照。共有39匹母马在入组时接受了预先随机分配的植入物治疗,植入物中含有2.2毫克或0毫克地洛瑞林。每天对公马进行诱情,并每隔24小时进行直肠超声检查,以确定排卵时间和发情持续时间。记录18(±3)天和38(±3)天时的配种次数和妊娠率,以及植入部位的全身副作用和局部反应。跟踪治疗发情期和/或下一个发情期配种所导致的妊娠情况,记录早期和晚期妊娠丢失率、足月妊娠数和活产驹数。地洛瑞林治疗组和安慰剂治疗组治疗时的平均卵泡直径分别为41.6毫米和40.8毫米,无显著差异。地洛瑞林STI治疗使排卵时间间隔从69.5±25.48小时显著缩短至42.7±12.35小时(p<0.001)。安慰剂组和地洛瑞林STI组在48小时内排卵的母马百分比分别从26.3%升至95.0%(p<0.001)。因此,地洛瑞林治疗的动物发情天数和需要多次配种的动物百分比显著降低,分别从5.4天降至4.6天,从55.6%降至5.0%(p = 0.009和 = 0.001)。地洛瑞林治疗组和安慰剂治疗组在治疗发情期(65.0%对44.4%)或下一个发情期(83.3%对92.3%)配种受孕的母马百分比令人满意且相似(p>0.005),在这些配种一次或两次的母马中,分别有70.0%和66.7%的妊娠足月并产下活驹。